Clinical Trial Update: Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

View source ↗

Summary

This completed clinical trial (NCT06344793) evaluated initial treatment with a CDK4/6 inhibitor plus endocrine therapy versus initial chemotherapy for HR-positi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor
• Chemotherapy (chemotherapy)
• Endocrine therapy

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Status: COMPLETED